==== Front F1000Res F1000Res F1000Research 2046-1402 F1000 Research Limited London, UK 10.12688/f1000research.132841.2 Method Article Articles Advancing posaconazole quantification analysis with a new reverse-phase HPLC method in its bulk and marketed dosage form [version 2; peer review: 2 approved] Rama Annamalai Investigation Methodology Writing – Original Draft Preparation https://orcid.org/0000-0002-5251-8560 1 Govindan Induja Investigation Writing – Original Draft Preparation 1 Hebbar Srinivas Supervision https://orcid.org/0000-0002-2459-4937 1 Chaturvedi Abhishek Supervision 2 Rani Usha Supervision https://orcid.org/0000-0001-9290-7854 3 Naha Anup Conceptualization Formal Analysis Funding Acquisition Project Administration Supervision Visualization a1 1 Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India 2 Division of Biochemistry, Department of Basic Medical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India 3 Department of Social Health and Innovation, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India a anup.naha@manipal.edu No competing interests were disclosed. 27 6 2023 2023 12 46823 6 2023 Copyright: © 2023 Rama A et al. 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction: Posaconazole is a widely used antifungal drug, and its accurate quantification is essential for quality control and assessment of its pharmaceutical products. This study aimed to develop and validate a reverse-phase high-performance liquid chromatography (HPLC) analytical method for quantifying Posaconazole in bulk and dosage form. Methods: The HPLC method was developed and validated based on International Conference on Harmonisation (ICH) guidelines. The developed method was then applied to quantify Posaconazole in a marketed tablet formulation. The method's specificity, linearity, precision, accuracy, robustness, and stability were evaluated. Results: The developed HPLC method showed good linearity over a 2-20 μg/mL concentration range. The percentage recovery of Posaconazole from the bulk and marketed formulations was found to be 99.01% and 99.05%, respectively. The intra-day and inter-day precisions were less than 1%, and the method was stable under different conditions. The HPLC method was successfully applied to quantify Posaconazole in the marketed formulation. Conclusion: The developed and validated HPLC method is reliable and efficient for analyzing Posaconazole in bulk and dosage forms. The method's accuracy, precision, specificity, linearity, robustness, and stability demonstrate its effectiveness. The method can be used for the quality control and assessment of Posaconazole-containing pharmaceutical products. Posaconazole HPLC Analytical method Validation Quality control Manipal Academy of Higher EducationThis study was supported by the Intramural fund of Manipal Academy of Higher Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Revised Amendments from Version 1 We have included a detailed discussion section on the new version of the manuscript and improved the quality of the article as per the editors and reviewers suggestion and comments. ==== Body pmcIntroduction Posaconazole is an antifungal medication that inhibits the synthesis of ergosterol, a vital component of the fungal cell membrane, ultimately causing cell death. It is effective against a wide range of fungal pathogens, making it a popular treatment for various fungal infections. Accurate and precise quantification of posaconazole in dosage forms is crucial for ensuring proper dosing and therapeutic efficacy, quality control, and pharmacokinetic studies. However, existing methods for measuring posaconazole can be expensive, time-consuming, or unreliable. 1 – 10 High-performance liquid chromatography (HPLC) is a commonly used analytical technique for quantifying drugs in dosage forms. This study aims to develop and validate a new HPLC analytical method that is quick, sensitive, robust, cheap, and reliable for estimating posaconazole in bulk and dosage form. 11 – 23 The HPLC method involves, ▪ Preparing a solution of the active ingredient from the dosage form, ▪ Injecting it into the HPLC system, and ▪ Separating the different components based on their interactions with the stationary phase. Posaconazole is detected using a UV-Vis detector, which measures the absorbance of posaconazole in the eluent. The peak area or height is then correlated to the concentration of posaconazole in the sample using a standard calibration curve. 24 – 34 The newly developed method was optimized by adjusting chromatographic conditions, including the mobile phase composition, column type, and detection wavelength. Validation was performed in accordance with International Conference on Harmonization (ICH) Q2 R1 guidelines, ensuring the method's accuracy, precision, and specificity. The method was successfully used to estimate posaconazole in its bulk and dosage forms. 35 – 49 Following CONSORT guidelines for reporting randomized trials increased the transparency of our study and improved the quality of our reporting, contributing to the overall usefulness of our findings. Our new analytical method has significant implications for drug delivery, including more accurate and efficient monitoring of posaconazole levels in patients, increasing overall drug efficacy and safety. Overall, this manuscript presents the development and validation of a new HPLC analytical method for estimating posaconazole in bulk and dosage form, which will provide valuable insights into analytical method development and validation for drug delivery and contribute to the ongoing efforts to improve patient outcomes. 50 – 63 Methods A HPLC Grade Milli-Q water (Milli Q Direct-Q 3 UV Water Purification System, Merck, United States), Analytical Weighing Balance (BSA224S-CW, Sartorius, Germany), UV Spectrophotometer (UV 1800, Shimadzu, Japan) was used in the study. Posaconazole was received as ex-gratis from Lupin Healthcare limited. Ortho-phosphoric acid (88%) was from Merck Ltd. (Mumbai, India). HPLC grade Acetonitrile (MeCN) and methanol (purity, min 99.8%), was procured from Merck Ltd. (Mumbai, India). A Nylon membrane filter of 0.45 μm was obtained from HiMedia Pvt. Ltd (Mumbai, India). Phenomenex Hyperclone C18 column (5 μm particle size, 100 Å, 250 mm × 4.6 mm id) was procured from Phenomenex (Hyderabad, India), Other reagents and solvents utilized for the method development and validation were of analytical or HPLC grade. The Shimadzu LC-2010CHT high-performance liquid chromatography model was used in the current research investigation. The device was equipped with a dual-wavelength ultraviolet detector, a column oven, and an autosampler from Shimadzu. The data acquisition of the chromatograms produced was done using LC Solution software version 5.57. A Hyperclone C18 column (250 mm x 4.6 mm in diameter, particle size 5 microns) from Phenomenex, USA. The mobile phase was filtered through a Millipore glass filter using 0.22-micron pore-size nylon membrane filter paper and connected to a glass vacuum filtration unit. The filtered mobile phase was then sonicated in a GT Sonic Professional Ultrasonic Cleaner)GT-2013QTS, GT Sonic, China) for 10 minutes to remove any air bubbles. The pH of the buffer was determined using a pH meter and a glass electrode (μ pH System 361, Systronics, India). Selection of wavelength Posaconazole was weighed and mixed with spectroscopy grade methanol to prepare the stock solution (10 mg in 10 mL). A series of concentrations (5 μg/mL, 10 μg/mL, 15 μg/mL, 20 μg/mL, 30 μg/mL) were prepared from the stock solution, and a UV spectrophotometer determined their absorbance maxima. The absorbance maxima were then used for the HPLC method development. 13 , 64 – 73 Selection of Stationary and Mobile Phase Choosing the right stationary and mobile phase is critical in HPLC method development. The underlying protocol for the selection of Stationary Phase and Mobile Phase is reposited in the Protocols.io repository which can be accessed by following these references. 74 , 75 To develop the method, the Phenomenex Hyperclone C18 column was selected as the stationary phase, and Acetonitrile and Methanol (as Organic Phase) and 10mM Phosphate buffer (pH 6.8) (Aqueous Phase) were chosen as the mobile phase. The stock solution was prepared in Acetonitrile, and an isocratic mode of elution was employed for the method. The injection volume was set to 20 microliters, and the detection wavelength was selected based on the absorbance maxima determined by UV. The stationary phase was maintained at 25°C, while the flow rate of the mobile phase varied between 0.8 and 1.2 mL per minute. From the stock solution, 1 μg/mL was prepared and used in the analysis. 10 mg of Posaconazole was weighed accurately and transferred to a 10 ml volumetric flask. The volume was made up with Acetonitrile to prepare the stock solution. From the stock solution 1 μg/mL was prepared. Isocratic mode of elution was opted for the method. Injection volume was set to 20 microliters and the detection wavelength was selected based on the results of the determination of absorbance maxima by UV. Stationary phase was maintained at 25 oC. Flow rate of the Mobile Phase was varied between 0.8 mL to 1.2 mL per minute. After the initial method development trials were conducted, an optimized trial was carried forward for analytical method validation according to ICH guidelines. 76 – 94 Validation of the optimized HPLC method The validation of an analytical method is critical for ensuring that the method is appropriate and reliable for its intended usage. In this study, the optimized analytical technique was subjected to a series of validation experiments recommended by the International Conference on Harmonization (ICH) Q2(R1) guidelines in order to evaluate its performance under various situations. 53 , 88 , 89 , 95 – 125 Specificity An analytical method's capability to accurately measure the analyte despite the presence of diluents or excipients in the sample is referred to as “specificity.” To assess the specificity of the optimized analytical method, three replicates of a blank solution (diluent), Posaconazole (1 μg/mL), and a commercial formulation (equivalent to 1 μg/mL of Posaconazole) were introduced into the HPLC system. The resulting chromatograms were then examined for any interference from the diluents or excipients at the retention time of the Posaconazole. Linearity Ensuring linearity is critical to analytical method development, as it guarantees accurate analyte quantification across a broad range of concentrations. To assess linearity, a range of serial concentrations, spanning from 0.1 to 32 μg/mL, were prepared from a standard Posaconazole drug solution using the mobile phase ratio as a diluent. Quintuplicate injections were made for each concentration, and the resulting peak areas (in mV-min) were plotted against their respective concentrations (in μg/mL) to create a linear regression graph. From this graph, the intercept and slope were calculated via a linear regression equation. Accuracy The accuracy of an analytical method is determined by its ability to produce results that are close to the true or accepted value of the measured concentration. To evaluate the accuracy of the developed method, three concentrations from the linearity range (2 μg/mL, 4 μg/mL, and 8 μg/mL) were analyzed in sextuplicate. Intra-day accuracy was assessed by analyzing sextuplicate injections of all three concentrations twice on the same day (at 09:00 and 21:00 hours), while inter-day accuracy was evaluated by analyzing duplicate injections of all three concentrations over three consecutive days. The mean percentage recovery was calculated for each concentration to determine the method's accuracy. Sensitivity Sensitivity is a crucial characteristic of an analytical method, as it determines the ability to detect small amounts of the analyte. In this study, the method's sensitivity was evaluated by determining Posaconazole's detection limit (DL) and quantitation limit (QL). The DL is defined as the lowest concentration of Posaconazole that can be detected with reliability and accuracy, while QL is the lowest concentration that can be measured with accuracy and precision. A lower DL and QL indicate a more sensitive method with the ability to detect and quantify low concentrations of the analyte. The DL and QL are calculated based on the residual standard deviation of the regression line and its slope. The formula is DL=3.3∗σS QL=10∗σS Where, σ = residual standard deviation of the regression line S = slope of the regression line Precision Precision is a critical parameter in evaluating the reliability and reproducibility of an analytical method. It assesses the agreement between multiple measurements of the same homogeneous sample under the same experimental conditions. In this study, the precision of the developed analytical method was determined by analyzing four quality control concentrations of Posaconazole, including the quantitation limit, the lower quality control concentration (three times the quantitation limit), higher quality control concentration (70% of the highest concentration from the linearity concentration), and middle-quality control concentration (the mean of the lower and higher quality control concentrations). Sextuplicate injections of all quality control solutions were analyzed twice on the same day at two different times (9:00 and 21:00) to assess intra-day precision. Additionally, duplicate injections of all quality control concentrations were analyzed for inter-day precision for three consecutive days. The peak area for each concentration and the percentage relative standard deviation (%RSD) were calculated to evaluate the method's inter- and intra-day precision. Robustness Robustness is a critical factor in assessing the stability and reliability of an analytical method. It ensures that minor variations in operating conditions do not significantly affect the method's performance. In this study, the robustness of the developed analytical method was evaluated by injecting a Posaconazole concentration of 2 μg/mL three times while varying certain conditions such as the acetonitrile ratio in the mobile phase (%), column oven temperature (°C), wavelength (nm), flow rate (mL/min), injection volume (μL), and pH of the aqueous phase. The responses were monitored for any changes, and each condition's peak area and retention time were analyzed to calculate the % RSD. System suitability System suitability is an essential aspect of the analytical method validation that assesses the performance of the entire analytical system to ensure that it is suitable for the intended analysis. This includes the evaluation of various parameters, such as peak area and retention time (Rt). To determine system suitability for the developed analytical method, a Posaconazole concentration of 1μg/mL was injected in sextuplicate, and the peak area and Rt for each injection were analyzed. The %RSD of these parameters was calculated to assess the overall performance of the analytical system. This helps ensure that the analytical system performs consistently and reliably, which is crucial for obtaining accurate and precise analytical results. Application of the developed analytical method for quantification of posaconazole in the marketed product The developed HPLC method is considered a valuable tool only after its practical application to quantify Posaconazole in dosage forms. Posaconazole was analyzed in the marketed tablet formulation (Picasa GR 100 mg Tablet, Manufactured by: MSN Laboratories, India, and Marketed by: Intas Pharmaceuticals Limited, India, Expiry Month and Year is April 2024) to test the method's practical feasibility. The marketed formulation's standard stock solution was prepared by accurately weighing 12.6 mg (equivalent to 10 mg of Posaconazole), transferring it to a 10 mL volumetric flask, and filling the volume with the mobile phase. Further dilutions were done with the mobile phase to obtain the desired concentration (1 μg/mL). The validated method was used to analyze the desired concentration, and the Rt and peak area were measured. The amount of Posaconazole in the desired concentration was calculated by comparing the peak areas. 33 , 126 – 134 Results Selection of wavelength The maximum absorbance was observed at 262.20 nm for all Posaconazole concentrations, leading to its selection as the optimal wavelength for subsequent HPLC analysis. This was evident with the Figure 1 which represents the UV spectrum of Posaconazole to determine its Absorption Maxima in different concentrations. Figure 1. UV spectrum of Posaconazole to determine its absorption maxima in different concentrations. Initial trials Thirteen different chromatograms were obtained by altering the ratios of the organic and mobile phases, as well as the flow rate, during the experimental trials. These chromatograms are depicted below. Trial No. 11 was selected as the optimized method due to its superior performance based on the obtained chromatograms from 13 different trials. The chosen conditions included a specific ratio of the organic phase and mobile phase, as well as a specific flow rate. The optimized method demonstrated excellent peak shape, a high peak area, and a suitable 5-to-8-minutes retention time. This ideal retention time range was considered to be optimal for bioanalytical method development as it allows for the elution of the drug without interference from plasma interferences that typically arise within the first 5 minutes while avoiding excessive consumption of mobile phase beyond 8 minutes, which can increase the cost of the method. Figure 2 shows the different chromatograms of initial trials of method development. Figure 2. Chromatograms of initial trials of method development. Optimized Method (Trial 11) Conditions Stationary Phase: Phenomenex Hyperclone C18 Column Mobile Phase: Acetonitrile: 10mM Phosphate Buffer pH 6.8 Mobile Phase Ratio: 55:45 Flow Rate: 1 ml/min Mode: Isocratic elution Column Temperature: 25 oC Detection Wavelength: 262 nm Total run time of the instrument: 10 minutes Validation of the optimized HPLC method The optimized HPLC method was validated according to the ICH Q2 (R1) guidelines, which involved a range of experiments to evaluate the method's performance under different conditions. Figure 3 shows the optimized chromatogram of the Posaconazole. Figure 3. Chromatogram of the Posaconazole with Blank. Specificity The developed HPLC method exhibited high specificity in determining Posaconazole, as indicated by the absence of interferences at the retention time of 7.634 minutes for pure Posaconazole and 7.691 minutes for the Posaconazole present in the marketed formulation. This suggests that the method is capable of accurately identifying Posaconazole in the presence of other components. Linearity Posaconazole was quantified in quintuplicate for a concentration range of 0.1 to 32 μg/mL. Individual linear plots were generated for each trial, and the mean value was computed. The plotted linear regression graph showed a linear regression equation of y = 58203x-3671 for the mean value, with a coefficient of determination (R 2) of 1. Notably, none of the consecutive R 2 values from the five linear regression plots was less than 0.999. This indicated that the optimized method was highly linear within the Posaconazole concentration range, and further experimentation was warranted. Figure 4 represents the linearity of the method via a linear graph. Figure 4. Mean linearity chart. Accuracy Intraday and interday analyses were conducted to assess the accuracy of the optimized HPLC method for quantifying Posaconazole. In the intraday analysis, sextuplicate injections were made at three different Posaconazole concentrations ranging from 2 to 8 μg/mL, while in the inter-day analysis, duplicate injections were made at the same three concentrations. The mean percentage recovery for each concentration was calculated and found to be 91.86%, 89.22%, and 87.46% for 2 μg/mL, 4 μg/mL, and 8 μg/mL, respectively, in the intraday analysis. Similarly, the mean percentage recovery for the inter-day analysis was 94.71%, 89.15%, and 88.09% for the same concentrations. The results showed that the mean recovery percentage for both intraday and inter-day analyses of Posaconazole was within the range of 85%-115%, indicating the optimized method's accuracy and suitability for the precise quantification of Posaconazole. Data represented in the Table 1 evident the accuracy of the method. Table 1. Accuracy of the method. Time in hours Concentration in mcg Retention time Area Linear equation % Recovery 0 2 7.632 102744 Y=58203x-3671 91.42 0 4 7.638 201361 88.07 0 8 7.633 401422 87.00 13 2 7.641 103262 91.86 13 4 7.639 204050 89.22 13 8 7.639 403561 87.46 26 2 7.644 106575 94.71 26 4 7.642 203875 89.15 26 8 7.646 406513 88.09 Sensitivity The detection limit is an important parameter in the analytical method validation process as it determines the lowest concentration of analyte that can be detected with acceptable accuracy and precision. In this study, the detection limit of Posaconazole was calculated based on the residual standard deviation of the regression line and its slope. The limit of detection and limit of quantitation were determined to be 0.24 and 0.74 μg/mL, respectively. This suggests that the developed HPLC method is highly sensitive and can detect Posaconazole even at very low concentrations. Precision Four quality control concentrations of Posaconazole were analyzed in duplicate during intraday and interday experiments to assess the precision of the developed analytical method. The mean peak area of the four concentrations (1.5 μg/mL, 4.5 μg/mL, 34.26 μg/mL, and 64 μg/mL) was calculated for both experiments. The results showed that the percentage relative standard deviation of the peak area for all concentrations was less than 2%, indicating the high precision of the method. This precision study confirms the suitability of the optimized method for the accurate quantification of Posaconazole. Therefore, the developed technique shows excellent potential for the precise quantification of Posaconazole, offering a reliable method for pharmaceutical research and analysis. Data represented in the Table 2 evident the precision of the method. Table 2. Precision of the method. Concentration in mcg 0 Hours 13 hours 26 hours %RSD Retention time Area Retention time Area Retention time Area Retention time Area 1.5 7.632 77441 7.641 78642 7.644 79113 0.08 1.01 4.5 7.638 194388 7.639 196151 7.642 197540 0.03 0.81 34.26 7.633 1695217 7.639 1718915 7.646 1732927 0.09 1.11 64 7.635 3213814 7.634 3253934 7.643 3233874 0.07 0.62 Robustness To assess the robustness of the developed HPLC analytical method, triplicate injections of Posaconazole at a concentration of 2 μg/mL were performed while varying the operating conditions such as the pH of the buffer, the acetonitrile ratio in the mobile phase, the column oven temperature, the wavelength, the flow rate, and the injection volume. The results showed that the mean percentage relative standard deviation (%RSD) of peak area and retention time were less than 2% for all the varied conditions. This indicates that the optimized methodology has a high degree of robustness, ensuring precise and accurate quantification of Posaconazole even in the presence of small variations in the operating conditions. Data represented in the Table 3 evident the robustness of the method. Table 3. Robustness of the method. Condition Retention time Area Standard retention time Standard area %RSD of retention time %RSD of area +2 nm Wavelength 7.641 102225 7.636 104890 0.04 1.82 -2 nm wavelength 7.628 102709 0.07 1.49 +0.2 ml Flow Rate 7.443 107548 1.81 1.77 -0.2 ml Flow Rate 7.851 102052 1.96 1.94 +0.2 pH 7.611 105729 0.23 0.56 -0.2 pH 7.698 105444 0.57 0.37 +2 mcl Injection Volume 7.637 107884 0.01 1.99 -2 mcl Injection Volume 7.635 102026 0.01 1.95 +2 oC Column Temperature 7.633 103537 0.02 0.92 -2 oC Column Temperature 7.634 103159 0.02 1.18 +2% Mobile Phase 7.594 103500 0.39 0.94 -2% Mobile Phase 7.688 104414 0.48 0.32 System suitability The suitability of the analytical system for the intended application of Posaconazole quantification in its bulk and dosage forms was evaluated by injecting Posaconazole at a concentration of 1 μg/mL in sextuplicate and analyzing the retention time and mean peak area. The consistent results obtained from the sextuplicate trials indicated the system's suitability for precise and accurate quantification of Posaconazole in its various forms. Data represented in the Table 4 evident the system suitability of the method. Table 4. System suitability of the method. Flow rate Rt Area NTP HETP TF 5% TF 10% K factor 1 7.634 55012 5910 25.382 1.132 1.107 1.62 1 7.637 55825 5797 25.874 1.133 1.105 1.62 1 7.635 55936 5848 25.65 1.135 1.105 1.62 1 7.635 55970 5858 25.605 1.132 1.103 1.62 1 7.636 56191 5766 26.014 1.135 1.106 1.62 1 7.637 55842 5828 25.736 1.131 1.102 1.62 %RSD 0.015861 0.727357 0.859556 0.856041 0.147689 0.168548 0.03 Application of the developed analytical method for quantification of Posaconazole in novel nanoformulations and marketed product The analytical method developed for quantifying Posaconazole was successfully applied to the practical analysis of Posaconazole in a marketed tablet formulation (Picasa GR 100, INTAS, India). This practical application demonstrated the feasibility and accuracy of the developed HPLC method in quantifying Posaconazole in real-world samples, indicating its potential as a reliable and efficient tool for quality control and assessment of Posaconazole-containing pharmaceutical products. The results highlight the effectiveness of the developed method in analyzing Posaconazole in dosage forms, affirming its potential as a valuable analytical tool for pharmaceutical industries. Quantification of Posaconazole in the marketed formulation The validated HPLC method was employed to determine the concentration of Posaconazole in the marketed tablet formulation (Picasa GR 100, INTAS, India). A standard stock solution of 10 μg/mL of Posaconazole was prepared and introduced into the HPLC system for analysis. The retention time and mean peak area were carefully recorded and analyzed to determine the concentration of Posaconazole. The analysis results indicated that the mean peak area and retention time of POSA were consistent with the anticipated values, which is a strong indication of the reliability of the analytical method. Moreover, the recovery percentage obtained from the analysis was 99%, signifying high precision and accuracy. These observations demonstrate the effectiveness of the HPLC method in determining the concentration of Posaconazole in the marketed formulation with high levels of reliability, precision, and accuracy. Discussion In this study, we successfully developed and validated a reverse-phase high-performance liquid chromatography (HPLC) method to accurately quantify Posaconazole in bulk and dosage forms. Accurate measurement of Posaconazole is crucial for ensuring the quality, safety, and effectiveness of pharmaceutical formulations. Our method addresses this need, offering a reliable and efficient approach for quality control and assessment of products containing this widely used antifungal drug. To ensure the reliability and robustness of our developed HPLC method, we applied specific acceptance criteria for the validation parameters. These acceptance criteria were as follows: 1. Specificity: The absence of interference in the retention time of posaconazole served as the acceptance criterion for specificity. This ensured that the developed method accurately identified and quantified posaconazole without any interference from other components. 2. Linearity: We assessed linearity using the coefficient of determination (R 2) value, with an acceptance criterion of R 2 greater than 0.999. This demonstrated a strong linear relationship between the analyte concentration and the corresponding peak area, ensuring accurate quantification across a range of concentrations. 3. Accuracy: Our acceptance criterion for accuracy was set at 85%-115%. This range ensured that the measured concentrations of posaconazole using our method fell within an acceptable percentage deviation from the true or expected values, indicating the method’s ability to provide accurate results. 4. Precision: For precision, we set the acceptance criterion as a percentage relative standard deviation (%RSD) of the peak area not exceeding 2%. This criterion evaluated the method’s repeatability and reproducibility by assessing the consistency of results obtained from multiple injections of the same sample. 5. Robustness: In terms of robustness, we used %RSD of area and retention time as acceptance criteria, with a maximum limit of 2%. This criterion evaluated the method’s ability to withstand deliberate variations in experimental conditions, while maintaining consistent and reliable results. Our method exhibited excellent linearity within a concentration range of 2-20 μg/mL, meeting the acceptance criterion for linearity (R 2 > 0.999). The accuracy of our method fell within the predefined acceptance range of 85%-115%, demonstrating its ability to provide accurate quantification. The precision results, with a %RSD of the peak area below 2%, confirmed the method’s repeatability and reproducibility. Additionally, the method showed robustness by maintaining consistent results within the accepted %RSD limits for area and retention time. One of the key advantages of our HPLC method lies in its simplicity and efficiency. With a straightforward sample preparation procedure and a relatively short analysis time, our method is practical for high-throughput analysis in diverse laboratory settings. Utilizing a commercially available HPLC column and a well-optimized mobile phase composition ensures optimal elution of Posaconazole. Moreover, our method offers high sensitivity and accuracy. It demonstrates excellent linearity across a wide concentration range, facilitating precise quantification of Posaconazole in different sample matrices. The method’s accuracy is supported by the close agreement between the measured concentrations and known reference standards. While our method shows robustness and reproducibility, we acknowledge certain limitations. Specifically, we did not investigate the potential impurities or contaminants that could interfere with the analysis. Exploring impurity profiling and assessing potential interferences would provide a more comprehensive understanding and enhance the method’s applicability. Future studies could focus on employing different extraction and purification techniques. These efforts would further enhance the reliability of our method and broaden its potential applications. The repeated analyses we conducted yielded highly consistent results, underscoring the reproducibility of our method. With its precision and accuracy confirmed through comparison with known reference standards, our method proves reliable for accurately quantifying Posaconazole. The comprehensive validation and repetition steps we undertook instill confidence in the method’s robustness and reliability across different experimental settings. While our method demonstrates robustness and reproducibility within the tested conditions, it is important to evaluate its performance when applied to different instruments or laboratories. Method transferability and inter-laboratory comparisons should be considered to ensure broader application and standardization. By providing a reliable and efficient means of analyzing Posaconazole, our developed method significantly contributes to the quality assurance and assessment of pharmaceutical products containing this drug. This is particularly valuable for ensuring the therapeutic effectiveness and safety of these formulations, ultimately benefiting patient care and treatment outcomes. In summary, our study successfully developed and validated an HPLC method for accurate Posaconazole quantification. The method’s reliability, simplicity, and high sensitivity make it suitable for widespread use in various pharmaceutical formulations and matrices. By adhering to specific acceptance criteria, we have established a robust and reliable method that meets stringent standards for specificity, linearity, accuracy, precision, and robustness. Conclusion In conclusion, this study successfully developed and validated a reverse-phase HPLC analytical method for quantifying Posaconazole in bulk and dosage forms. The method showed excellent linearity, precision, accuracy, and specificity. The study adhered to the CONSORT guidelines, ensuring the validity and reproducibility of the results. This analytical method can be used for quality control and assessment of Posaconazole-containing pharmaceutical products, thereby contributing to the development of safe and effective drugs for patients. Acknowledgements We thank all the colleagues of Department of Pharmaceutics, MCOPS, MAHE for their support. Data availability FigShare. Linearity Data of Posaconazole HPLC estimation. DOI: https://doi.org/10.6084/m9.figshare.22331650 This project contains the following underlying data: Linearity Data of Posaconazole HPLC estimation a. The above-mentioned dataset represents the linearity of the develop HPLC method for Posaconazole estimation. Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication). 10.5256/f1000research.152016.r181903 Reviewer response for version 2 Dave Vivek 1Referee https://orcid.org/0000-0001-7337-6365 1 Department of Pharmacy, School of Health Science, Central University of South Bihar, Patna, Bihar, India 30 6 2023 Copyright: © 2023 Dave V 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Version 2recommendationapprove Now the article has been accepted in this revised current form. Is the rationale for developing the new method (or application) clearly explained? Yes Is the description of the method technically sound? Yes Are the conclusions about the method and its performance adequately supported by the findings presented in the article? Yes If any results are presented, are all the source data underlying the results available to ensure full reproducibility? Yes Are sufficient details provided to allow replication of the method development and its use by others? Yes Reviewer Expertise: Pharmaceutics, NDDS I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. 10.5256/f1000research.152016.r181902 Reviewer response for version 2 Deshpande Praful Balavant 1Referee 1 Teva Pharmaceuticals, Waterford, Ireland 27 6 2023 Copyright: © 2023 Deshpande PB 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Version 2recommendationapprove Satisfied with the author response and this article can be accepted without further changes. Is the rationale for developing the new method (or application) clearly explained? Yes Is the description of the method technically sound? Yes Are the conclusions about the method and its performance adequately supported by the findings presented in the article? Yes If any results are presented, are all the source data underlying the results available to ensure full reproducibility? Yes Are sufficient details provided to allow replication of the method development and its use by others? Yes Reviewer Expertise: Pharmaceutical Research & Development I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. 10.5256/f1000research.145793.r172005 Reviewer response for version 1 Dave Vivek 1Referee https://orcid.org/0000-0001-7337-6365 1 Department of Pharmacy, School of Health Science, Central University of South Bihar, Patna, Bihar, India 24 5 2023 Copyright: © 2023 Dave V 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Version 1recommendationapprove-with-reservations The manuscript describes the development and validation of a new reverse-phase HPLC method for quantifying posaconazole in bulk and marketed dosage forms. The study was conducted following ICH guidelines, and the results demonstrate the effectiveness of the developed method in accurately quantifying posaconazole over a concentration range of 2-20 μg/mL. Overall, the manuscript is well-written and organized, with clear descriptions of the methods and results. However, there are a few minor issues that should be addressed before indexing: The authors should provide more information on the sources of posaconazole used in the study, particularly the marketed tablet formulation. For example, what brand or manufacturer was used, and was the formulation within the expiration date? It would be helpful if the authors could provide more information on the selectivity of the developed HPLC method. For example, were there any potential impurities or contaminants that could interfere with the analysis, and if so, how were they controlled for? In Table 3, the % RSD values for precision should be expressed to two decimal places. The authors should consider expanding the discussion section to further emphasize the significance of the study's findings. Finally, there are a few minor grammatical errors and typos throughout the manuscript that should be corrected before indexing. Overall, I believe this manuscript presents valuable insights into the quantification of posaconazole and provides an important contribution to the field of pharmaceutical analysis. Is the rationale for developing the new method (or application) clearly explained? Yes Is the description of the method technically sound? Yes Are the conclusions about the method and its performance adequately supported by the findings presented in the article? Yes If any results are presented, are all the source data underlying the results available to ensure full reproducibility? Yes Are sufficient details provided to allow replication of the method development and its use by others? Yes Reviewer Expertise: Pharmaceutics, NDDS I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Rama Annamalai Pharmaceutics, Manipal Academy of Higher Education, Manipal, Karnataka, India 23 6 2023 Dear Reviewer, Thank you for taking the time to review our manuscript titled "Development and Validation of a Reverse-Phase HPLC Method for Quantifying Posaconazole in Bulk and Marketed Dosage Forms." We appreciate your valuable feedback and have made the necessary revisions to address your concerns. Here is a detailed response to each of your points: 1. Sources of Posaconazole: We have now provided additional information regarding the sources of posaconazole used in our study, including the brand or manufacturer of the marketed tablet formulation. We have also mentioned that the formulation used was within the expiration date. 2. Selectivity of the Developed HPLC Method: We have included a discussion section in the manuscript that provides more information on the selectivity of our developed HPLC method. 3. Precision Values in Table 3: We have revised Table 3 to express the %RSD values for precision to two decimal places, as per your suggestion. 4. Expanded Discussion Section: We have expanded the discussion section of the manuscript to further emphasize the significance of our study's findings. We have provided a more comprehensive analysis of the results and their implications, highlighting the potential applications and benefits of the developed method. 5. Grammar and Typographical Errors: We have carefully reviewed the entire manuscript, addressing any grammatical errors and typos. We utilized Grammarly Premium University Version to ensure the accuracy of the language and to enhance the overall quality of the manuscript. We would like to express our gratitude for your insightful comments and assure you that we have taken them seriously. We believe that the revisions we have made have significantly improved the manuscript. Thank you once again for your time and expertise in reviewing our manuscript. 10.5256/f1000research.145793.r172003 Reviewer response for version 1 Deshpande Praful Balavant 1Referee 1 Teva Pharmaceuticals, Waterford, Ireland 18 5 2023 Copyright: © 2023 Deshpande PB 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Version 1recommendationapprove The manuscript presents a new reverse-phase HPLC method for quantifying posaconazole in bulk and marketed dosage forms. The study was well-designed and executed, and the results demonstrate the effectiveness of the developed method in accurately quantifying posaconazole within a concentration range of 2-20 μg/mL. Overall, the manuscript is well-written and organized, with clear descriptions of the methods and results. However, there are a few minor issues that should be addressed before indexing: The authors should provide more information on the validation parameters used in the study, particularly the acceptance criteria for accuracy and precision. In Table 2, it would be helpful if the authors could provide a brief explanation of the abbreviations used for the mobile phase and detection wavelength. The authors should consider adding a brief discussion of the advantages and limitations of the developed HPLC method compared to other methods for quantifying posaconazole. It would be helpful if the authors could provide more information on the reproducibility of the method. Finally, there are a few minor grammatical errors and typos throughout the manuscript that should be corrected before indexing. I believe this study offers valuable new perspectives on posaconazole quantification and represents a significant contribution to the field of pharmaceutical analysis. With only minor revisions required, I recommend Approving the manuscript for indexing. Is the rationale for developing the new method (or application) clearly explained? Yes Is the description of the method technically sound? Yes Are the conclusions about the method and its performance adequately supported by the findings presented in the article? Yes If any results are presented, are all the source data underlying the results available to ensure full reproducibility? Yes Are sufficient details provided to allow replication of the method development and its use by others? Yes Reviewer Expertise: Pharmaceutical Research & Development I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Rama Annamalai Pharmaceutics, Manipal Academy of Higher Education, Manipal, Karnataka, India 23 6 2023 Dear Reviewer, Thank you for your thoughtful review of our manuscript titled "Development and Validation of a Reverse-Phase HPLC Method for Quantifying Posaconazole in Bulk and Marketed Dosage Forms." We greatly appreciate your positive feedback and your valuable suggestions for improvement. We have carefully addressed each of your points, and we are pleased to inform you that we have made the necessary revisions. Here is our detailed response: 1. Validation Parameters: We have now provided additional information about the validation parameters used in the study, specifically the acceptance criteria for accuracy and precision. We have included this information in the discussion section, which allows readers to better understand the reliability and robustness of our developed HPLC method. 2. Explanation of Abbreviations in Table 2: We have made the required changes as per your suggestion. 3. Advantages and Limitations of the Developed HPLC Method: We have included a brief discussion in the manuscript that highlights the advantages and limitations of our developed HPLC method compared to other methods for quantifying posaconazole. This addition will help readers appreciate the unique features and potential applications of our method. 4. Reproducibility Information: We have addressed your suggestion and provided more detailed information on the reproducibility of our method in the discussion section of the manuscript. We discuss the precision and repeatability of the method and provide insights into the robustness and reliability of our results. 5. Grammar and Typographical Errors: We have meticulously reviewed the entire manuscript, correcting any grammatical errors and typographical mistakes. We utilized Grammarly Premium University Version to ensure the accuracy of the language and enhance the overall quality of the manuscript. We sincerely thank you for your positive evaluation of our study and your recommendation to approve the manuscript for indexing. We are grateful for your time and expertise in reviewing our work, and we believe that the revisions we have made have significantly improved the manuscript. Once again, we extend our gratitude for your valuable feedback and your recommendation to approve our manuscript. Competing interests: No competing interests were disclosed. Competing interests: No competing interests were disclosed. Competing interests: No competing interests were disclosed. Competing interests: None Competing interests: No competing interests were disclosed. Competing interests: None ==== Refs Bibliography 1 Abou El-Alamin MM Sultan MA Atia MA : Novel Application of Pentabromobenzyl Column for Simultaneous Determination of Eight Antifungal Drugs Using High-performance Liquid Chromatography. Comb. Chem. High Throughput Screen. 2020;23 (10 ):991–1001. 10.2174/1386207323666200220114818 32077818 2 Alffenaar JWC Wessels AMA Hateren K van : Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009;878 (1 ):39–44. 10.1016/j.jchromb.2009.11.017 19945360 3 Gomez-Lopez A Alcazar-Fuoli L Bernal-Martínez L : Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC/PDA: role of azole metabolic rate. Diagn. Microbiol. Infect. Dis. 2018;92 (1 ):78–83. 10.1016/j.diagmicrobio.2018.04.003 29778564 4 Allegra S Fatiguso G De Francia S : Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection. Biomedicines. 2017;5 (4 ). 10.3390/biomedicines5040066 29156624 5 Araújo JIR de Moura FL de Soares MFLR : Stability study and oxidative degradation kinetics of posaconazole. Microchem. J. 2019;151 :104181. 10.1016/j.microc.2019.104181 6 Assress HA Nyoni H Mamba BB : Target quantification of azole antifungals and retrospective screening of other emerging pollutants in wastewater effluent using UHPLC –QTOF-MS. Environ. Pollut. 2019;253 :655–666. 10.1016/j.envpol.2019.07.075 31330357 7 Baietto L D’Avolio A Ventimiglia G : Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob. Agents Chemother. 2010;54 (8 ):3408–3413. 10.1128/AAC.01807-09 20530230 8 Baietto L D’avolio A Marra C : Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. J. Antimicrob. Chemother. 2012;67 (11 ):2645–2649. 10.1093/jac/dks285 22872447 9 Basu SS Petrides A Mason DS : A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum. Clin. Chem. Lab. Med. 2017;55 (6 ):836–844. 10.1515/cclm-2016-0418 27866173 10 Beste KY Burkhardt O Kaever V : Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clin. Chim. Acta. 2012;413 (1-2 ):240–245. 10.1016/j.cca.2011.09.042 21996080 11 Garcia CV Bitencourt AS Oliveira SS : Analytical Study of the Antifungal Posaconazole in Raw Material: Quantitative Bioassay, Decomposition Chemical Kinetics, and Degradation Impurities by LC-QTOF-MS. J. AOAC Int. 2021;104 (4 ):1055–1064. 10.1093/jaoacint/qsab009 33470411 12 Garcia CV Bitencourt AS Oliveira SS : Analytical Study of the Antifungal Posaconazole in Raw Material: Quantitative Bioassay, Decomposition Chemical Kinetics, and Degradation Impurities by LC-QTOF-MS. J. AOAC Int. 2021;104 (4 ):1055–1064. 10.1093/jaoacint/qsab009 33470411 13 Virginia Garcia C Bitencourt AS da Oliveira SS : UV Spectrophotometric method for determination of posaconazole: comparison to HPLC. Journal of Basic and Applied Pharmaceutical Sciences Rev Ciênc Farm Básica Apl. 2015;36 (4 ):491–495. 14 Bressán IG Mendez ML Gimenez MI : Validation of a Reversed-Phase Ultra-High-Performance Liquid Chromatographic Method with Photodiode Array Detection for the Determination of Voriconazole in Human Serum and Its Application to Therapeutic Drug Monitoring. Ther. Drug Monit. 2018;40 (2 ):276–283. 10.1097/FTD.0000000000000491 29432386 15 Buckner SL Ceesay MM Pagliuca A : Measurement of Posaconazole, Itraconazole, and Hydroxyitraconazole in Plasma/Serum by High-Performance Liquid Chromatography With Fluorescence Detection. 16 Couchman L Buckner SL Morgan PE : An automated method for the simultaneous measurement of azole antifungal drugs in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2012;404 :513–523. 10.1007/s00216-012-6176-3 22695504 17 Cáceres DH Zapata JD Granada SD : Estandarización y validación en Colombia de una metodología basada en HPLC para la determinación de la concentración sérica de posaconazol. Rev. Iberoam. Micol. 2016;33 (4 ):230–236. 10.1016/j.riam.2015.09.002 27663097 18 Campoli P Al Abdallah Q Robitaille R : Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 2011;55 (12 ):5732–5739. 10.1128/AAC.00637-11 21930891 19 Chae H Cho SY Yu H : Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy. Clin. Chim. Acta. 2015;450 :220–226. 10.1016/j.cca.2015.08.023 26319883 20 Chahbouni A Wilhelm AJ Den Burger JCG : Validated Liquid Chromatography-Tandem Mass Spectroscopy Method for the Simultaneous Quantification of Four Antimycotic Agents in Human Serum. 21 Chhun S Rey E Tran A : Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007;852 (1-2 ):223–228. 10.1016/j.jchromb.2007.01.021 17306633 22 Crombag MRBS Huisman C Kemper EM : Posaconazole Treatment in Hematology Patients: A Pilot Study of Therapeutic Drug Monitoring. 23 Cunliffe JM Noren CF Hayes RN : A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: Implementing fused core silica liquid chromatography. J. Pharm. Biomed. Anal. 2009;50 (1 ):46–52. 10.1016/j.jpba.2009.03.034 19442473 24 Decosterd LA Rochat B Pesse B : Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob. Agents Chemother. 2010;54 (12 ):5303–5315. 10.1128/AAC.00404-10 20855739 25 Docci L Klammers F Ekiciler A : In Vitro to in vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. AAPS Journal. 2020;22 (6 ):131. 10.1208/s12248-020-00482-9 33051808 26 Prasad VD Reddy VR Aparna P : Validated Gradient Stability Indicating UPLC Method for the Determination of Related Substances of Posaconazole in Bulk Drug. Am. J. Anal. Chem. 2015;06 (12 ):965–976. 10.4236/ajac.2015.612092 27 Durgun ME Kahraman E Güngör S : Optimization and Characterization of Aqueous Micellar Formulations for Ocular Delivery of an Antifungal Drug, Posaconazole. Curr. Pharm. Des. 2020;26 (14 ):1543–1555. 10.2174/1381612826666200313172207 32167423 28 Elkhabaz A Sarkar S Simpson GJ : Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media. Pharm. Res. 2019;36 (12 ):174. 10.1007/s11095-019-2718-0 31667638 29 Elkhabaz A Moseson DE Brouwers J : Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids. Mol. Pharm. 2019;16 :5042–5053. 10.1021/acs.molpharmaceut.9b00956 31638397 30 Elkhabaz A Moseson DE Sarkar S : Crystallization Kinetics in Fasted-State Simulated and Aspirated Human Intestinal Fluids. Cryst. Growth Des. 2021;21 (5 ):2807–2820. 10.1021/acs.cgd.0c01730 31 Farowski F Cornely OA Vehreschild JJ : Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 2010;54 (5 ):1815–1819. 10.1128/AAC.01276-09 20176892 32 Fatiguso G Favata F Zedda I : A simple high performance liquid chromatography–mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. J. Pharm. Biomed. Anal. 2017;145 :718–724. 10.1016/j.jpba.2017.07.040 28806568 33 Xu F Xu Y Liu G : Separation of twelve posaconazole related stereoisomers by multiple heart-cutting chiral–chiral two-dimensional liquid chromatography. J. Chromatogr. A. 2020;1618 :460845. 10.1016/j.chroma.2019.460845 31924329 34 Feng W Liu H Chen G : Structural Characterization of the Oxidative Degradation Products of an Antifungal Agent SCH 56592 by LC-NMR and LC-MS. 2001;25 . Reference Source 35 Franceschi L D’Aronco S Furlanut M : Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of voriconazole and posaconazole in serum samples from patients with invasive mycoses. J. Bioanal. Biomed. 2011;03 (5 ):92–97. 10.4172/1948-593X.1000050 36 Fule R Amin P : Hot Melt Extruded Amorphous Solid Dispersion of Posaconazole with Improved Bioavailability: Investigating Drug-Polymer Miscibility with Advanced Characterisation. Biomed. Res. Int. 2014;2014 :1–16. 10.1155/2014/146781 25143935 37 Garcia CV Costa GR Mendez ASL : Stability-indicating HPLC method for posaconazole bulk assay. Sci. Pharm. 2012;80 (2 ):317–327. 10.3797/scipharm.1111-11 22896819 38 Garg EU : Clinical Applications of Mass Spectrometry in Drug Analysis Methods and Protocols Methods in Molecular Biology 1383. Reference Source 39 Gharibi S Kimble B Vogelnest L : Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration. J. Vet. Pharmacol. Ther. 2017;40 (6 ):675–681. 10.1111/jvp.12407 28455999 40 Ghosal A Hapangama N Yuan Y : IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL). 2004. 41 Gordien JB Pigneux A Vigouroux S : Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J. Pharm. Biomed. Anal. 2009;50 (5 ):932–938. 10.1016/j.jpba.2009.06.030 19608374 42 Greenblatt DJ Harmatz JS Ryan MJ : Sustained Impairment of Lurasidone Clearance after Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. J. Clin. Psychopharmacol. 2018;38 (4 ):289–295. 10.1097/JCP.0000000000000892 29851709 43 Hamdy DA Belal TS : A comparative study of newly developed HPLC-DAD and UHPLC-UV assays for the determination of posaconazole in bulk powder and suspension dosage form. J. Anal. Methods Chem. 2014;2014 :1–7. 10.1155/2014/241035 25258695 44 Choudhary H Singh S Singh R : Rapid and Simple Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) Method for Simultaneous Quantifications of Triazole Antifungals in Human Serum. Mycopathologia. 2021;186 (1 ):27–39. 10.1007/s11046-020-00514-0 33389486 45 Henry H Sobhi HR Scheibner O : Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 2012;26 (5 ):499–509. 10.1002/rcm.6121 22302489 46 Jenkins N Black M Schneider HG : Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS/MS. Clin. Biochem. 2018;53 :110–115. 10.1016/j.clinbiochem.2018.01.004 29325818 47 Kahle K Langmann P Schirmer D : Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob. Agents Chemother. 2009;53 (7 ):3140–3142. 10.1128/AAC.00213-09 19380591 48 Kai M Tanaka R Suzuki Y : Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method. Clin. Biochem. 2021;90 :40–49. 10.1016/j.clinbiochem.2021.01.012 33539809 49 Kathirvel S Raju R Seethadevi B : Stability Indicating RP-HPLC Method for the Determination of Process Related Impurities in Posaconazole API. 2014;4 . Reference Source 50 Pathak SM Kumar AR Musmade P : A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma-Application to preclinical pharmacokinetics. Talanta. 2008;76 (2 ):338–346. 10.1016/j.talanta.2008.02.047 18585287 51 Pathak SM Kumar AR Subramanian G : Development and validation of a reversed-phase liquid chromatographic method with fluorescence detection for the study of Saquinavir pharmacokinetics in rat plasma. Anal. Chim. Acta. 2007;594 (2 ):248–256. 10.1016/j.aca.2007.05.028 17586122 52 Pathak SM Musmade PB Bhat KM : Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. Bioanalysis. 2010;2 (1 ):95–104. 10.4155/bio.09.162 21083123 53 Attari Z Kumar L Mallikarjuna Rao C : Reversed-Phase HPLC Method for Determination of Temozolomide in Rat Plasma and Brain: Simple, Sensitive and Robust Method. Pharm. Chem. J. 2018;52 (3 ):266–270. 10.1007/s11094-018-1804-7 54 Kumar L Sreenivasa Reddy M Managuli RS : Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles. Saudi Pharm. J. 2015;23 (5 ):549–555. 10.1016/j.jsps.2015.02.001 26594122 55 Bhaskaran NA Kumar L Reddy MS : An analytical “quality by design” approach in RP-HPLC method development and validation for reliable and rapid estimation of irinotecan in an injectable formulation. Acta Pharma. 2021;71 (1 ):57–79. 10.2478/acph-2021-0008 56 Mutalik SP Mullick P Pandey A : Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co-loaded in nano-liposomes. J. Sep. Sci. 2021;44 (15 ):2917–2931. 10.1002/jssc.202100152 34076952 57 Hegde AR Padya BS Soman S : A simple, precise, and sensitive HPLC method for quantification of letrozole in rat plasma: development, validation, and preclinical pharmacokinetics. J. Anal. Sci. Technol. 2021;12 (1 ). 10.1186/s40543-021-00276-4 58 Padya BS Hegde AR Mutalik SP : Analytical and bioanalytical HPLC method for simultaneous estimation of 5-fluorouracil and sonidegib. Bioanalysis. 2022;14 (1 ):29–45. 10.4155/bio-2021-0212 34786955 59 Managuli RS Gourishetti K Shenoy RR : Preclinical pharmacokinetics and biodistribution studies of asenapine maleate using novel and sensitive RP-HPLC method. Bioanalysis. 2017;9 (14 ):1037–1047. 10.4155/bio-2017-0069 28737445 60 Sree N Dengale SJ Mutalik S : Dronedarone HCl-Quercetin Co-amorphous System: Characterization and RP-HPLC Method Development for Simultaneous Estimation. 2020. 10.1093/jaoacint/qsab024/6149120 61 Mullick P Mutalik SP Hegde AR : Simultaneous Estimation of Apremilast and Betamethasone Dipropionate in Microsponge-Based Topical Formulation using a Stability Indicating RP-HPLC Method: A Quality-by-Design Approach. J. Chromatogr. Sci. 2021;59 (10 ):928–940. 10.1093/chromsci/bmab016 33618363 62 Managuli RS Kumar L Chonkar AD : Development and Validation of a Stability-Indicating RP-HPLC Method by a Statistical Optimization Process for the Quantification of Asenapine Maleate in Lipidic Nanoformulations. J. Chromatogr. Sci. 2016;54 (8 ):1290–1300. 10.1093/chromsci/bmw062 27130879 63 Marghade S Musmade PB Moorkoth S : High-performance liquid chromatographic assay for ziprasidone in plasma samples: Application to pharmacokinetic studies in rats. J. Chromatogr. Sci. 2012;50 (10 ):902–908. 10.1093/chromsci/bms088 22677485 64 Kim H Kumari P Lin CC : Simultaneous High-Performance Liquid Chromatographic Determination of SCH 59884 (Phosphate Ester Prodrug of SCH 56592), SCH 207962 and SCH 56592 in Dog Plasma. 2002;27 . Reference Source 65 Kim H Likhari P Kumari P : High-Performance Liquid Chromatographic Analysis of the Anti-Fungal Agent SCH 56592 in Dog Serum. 2000;738 . Reference Source 66 Kim H Lin CC Laughlin M : Chiral High-Performance Liquid Chromatographic Analysis of Antifungal SCH 56592 and Evaluation of Its Chiral Inversion in Animals and Humans. 2000;12 . 67 Kim H Kumari P Laughlin M : U Se of High-Performance Liquid Chromatographic and Microbiological Analyses for Evaluating the Presence or Absence of Active Metabolites of the Antifungal Posaconazole in Human Plasma. 2003;987 . Reference Source 68 Kourentas A Vertzoni M Symillides M : In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. Int. J. Pharm. 2016;515 (1-2 ):352–358. 10.1016/j.ijpharm.2016.10.018 27732895 69 Kourentas A Vertzoni M Barmpatsalou V : The BioGIT System: a Valuable in vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS Journal. 2018;20 (4 ):71. 10.1208/s12248-018-0231-8 29797293 70 Krieter P Flannery B Musick T : Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 2004;48 (9 ):3543–3551. 10.1128/AAC.48.9.3543-3551.2004 15328123 71 Krüger R Vogeser M Burghardt S : Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry. Clin. Chem. Lab. Med. 2010;48 (12 ):1723–1731. 10.1515/CCLM.2010.333 20704538 72 Lignell A Löwdin E Cars O : Posaconazole in human serum: A greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob. Agents Chemother. 2011;55 (7 ):3099–3104. 10.1128/AAC.01671-10 21502622 73 Locatelli M Kabir A Innosa D : A fabric phase sorptive extraction-High performance liquid chromatography-Photo diode array detection method for the determination of twelve azole antimicrobial drug residues in human plasma and urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2017;1040 :192–198. 10.1016/j.jchromb.2016.10.045 27856196 74 annamalai.rama, annamalai.rama: Selection of Stationary Phase of HPLC for Posaconazole Estimation. protocols.io. March 2023. 75 annamalai.rama, annamalai.rama: Selection of buffer for the HPLC estimation of Posaconazole. protocols.io. March 2023. 76 Mahaparale SP Yadav AM Mahaparale S : BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF POSACANAZOLE BY RP-HPLC METHOD. 77 McShane AJ Wang S : Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite. Clin. Chim. Acta. 2017;474 :8–13. 10.1016/j.cca.2017.08.032 28864232 78 Mistretta V Dubois N Denooz R : Simultaneous determination of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection. Acta Clin. Belg. 2014;69 (1 ):53–61. 10.1179/0001551213Z.00000000018 24635400 79 Molinelli AR Rose CH : Quantification of the triazole antifungal compounds voriconazole and posaconazole in human serum or plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS/MS). Methods in Molecular Biology. Vol.1383 . Humana Press Inc.;2016; pp.39–47. 10.1007/978-1-4939-3252-8_5 26660172 80 Moseson DE Jordan MA Shah DD : Application and limitations of thermogravimetric analysis to delineate the hot melt extrusion chemical stability processing window. Int. J. Pharm. 2020;590 :119916. 10.1016/j.ijpharm.2020.119916 32979452 81 Mueller SC Karasch I Lakner J : Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications. 2018. Reference Source 82 Müller C Gehlen D Blaich C : Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum. Ther. Drug Monit. 2017;39 (5 ):505–513. 10.1097/FTD.0000000000000438 28742650 83 Störzinger D Swoboda S Lichtenstern C : Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin. Chem. Lab. Med. 2008;46 (12 ):1747–1751. 10.1515/CCLM.2008.338 18973464 84 Nasser ST Abdulrassol AA : Formulation and characterization of anti-fungal (Posaconazole) o/w nanoemulsion. Int. J. Drug Deliv.. 2021;11 (2 ):322–328. 10.25258/ijddt.11.2.15 85 Neubauer W König A Bolek R : Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009;877 (24 ):2493–2498. 10.1016/j.jchromb.2009.06.022 19577524 86 Nomeir AA Kumari P Hilbert MJ : Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys. 2000;44 . Reference Source 87 Patel A Patel K Patel K : Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19–associated mucormycosis in a real-life setting. Mycoses. 2022;65 (3 ):312–316. 10.1111/myc.13420 34953080 88 Patel K Verriboina SK Vasantharaju SG : Stability indicating assay method development and validation of simultaneous estimation of chlorzoxazone, diclofenac sodium and paracetamol in bulk drug and tablet by RP-HPLC. Res. J. Pharm. Technol. 2021;14 (9 ):5024–5028. 10.52711/0974-360X.2021.00876 89 Krishna V Reddy MS : Isocratic High Performance Liquid Chromatographic (HPLC) Determination of Rifampicin in Presence of Isoniazid. Res. J. Pharm. Tech. 2014;7 (3 ). Reference Source 90 Rochat B Pascual A Pesse B : Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing. Antimicrob. Agents Chemother. 2010;54 (12 ):5074–5081. 10.1128/AAC.00022-10 20921320 91 Ruan LH Fan LL Wang K : The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS. Front. Pharmacol. 2021;12 :12. 10.3389/fphar.2021.749169 34912218 92 Santana ACSGV Danda LJDA Nunes LCC : Simultaneous Quantification of Benznidazole and Posaconazole by HPLC-DAD Using QbD Approach. J. Chromatogr. Sci. 2019;57 (2 ):156–162. 10.1093/chromsci/bmy097 30496348 93 Santana ACSGV Nadvorny D Rocha Passos TD da : Influence of cyclodextrin on posaconazole stability, release and activity: Improve the utility of the drug. J. Drug Deliv. Sci. Technol. 2019;53 :101153. 10.1016/j.jddst.2019.101153 94 Schuster C Paal M Lindner J : Isotope dilution LC-orbitrap-HRMS with automated sample preparation for the simultaneous quantification of 11 antimycotics in human serum. J. Pharm. Biomed. Anal. 2019;166 :398–405. 10.1016/j.jpba.2019.01.038 30711809 95 Shen JX Krishna G Hayes RN : A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 2007;43 (1 ):228–236. 10.1016/j.jpba.2006.06.011 16859858 96 Shen JX Tama CI Hayes RN : Evaluation of automated micro solid phase extraction tips (μ-SPE) for the validation of a LC-MS/MS bioanalytical method. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006;843 (2 ):275–282. 10.1016/j.jchromb.2006.06.039 97 Skaggs CL Ren GJ Elgierari ETM : Simultaneous quantitation of five triazole anti-fungal agents by paper spray-mass spectrometry. Clin. Chem. Lab. Med. 2020;58 (5 ):836–846. 10.1515/cclm-2019-0895 31926066 98 Škríba A Patil RH Hubáček P : Rhizoferrin glycosylation in rhizopus microsporus. J. Fungi. 2020;6 (2 ):1–10. 10.3390/jof6020089 32570979 99 Smith A Dowis J French D : Quantification of Serum Voriconazole, Isavuconazole, and Posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Curr. Protoc. Toxicol. 2018;76 (1 ):e47. 10.1002/cptx.47 30040225 100 Tang PH : Determination of posaconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection. Separations. 2017;4 (2 ). 10.3390/separations4020016 101 Tang S Chen J Cannon J : Dendrimer-based posaconazole nanoplatform for antifungal therapy Dendrimer-based posaconazole nanoplatform for antifungal therapy. Drug Deliv. 2021;28 (1 ):2150–2159. 10.1080/10717544.2021.1986605 34617850 102 Tang S Chen J Cannon J : Dendrimer-based posaconazole nanoplatform for antifungal therapy. Drug Deliv. 2021;28 (1 ):2150–2159. 10.1080/10717544.2021.1986605 34617850 103 Toussaint B Lanternier F Woloch C : An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2017;1046 :26–33. 10.1016/j.jchromb.2017.01.036 28131025 104 Verdier MC Bentué-Ferrer D Tribut O : Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma. Clin. Chem. Lab. Med. 2010;48 (10 ):1515–1522. 10.1515/CCLM.2010.252 20557278 105 Vogeser M Rieger C Ostermann H : A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. Clin. Chem. Lab. Med. 2009;47 (5 ):579–584. 10.1515/CCLM.2009.129 19302035 106 Wadsworth JM Milan AM Anson J : Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole. Ann. Clin. Biochem. 2017;54 (6 ):686–695. 10.1177/0004563216686378 27941128 107 Dabir J Mathew EM Moorkoth S : Analytical method development and validation of RP-HPLC method for simultaneous estimation of N-acetyl cysteine and cefexime from its fixed dose combination. Res. J. Pharm. Technol. 2016;9 (7 ):835–842. 10.5958/0974-360X.2016.00158.X 108 Mathew EM Moorkoth S Rane PD : Cost-Effective HPLC-UV Method for Quantification of Vitamin D 2 and D 3 in Dried Blood Spot: A Potential Adjunct to Newborn Screening for Prophylaxis of Intractable Paediatric Seizures. 2019;88 . 109 Tejasvini CS Sekhar S Verma R : DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING ASSAY RP-HPLC METHOD FOR THE ESTIMATION OF ANIDULAFUNGIN AND RELATED COMPOUNDS IN PARENTERAL DOSAGE FORM. Rasayan J. Chem. 2022;15 (1 ):280–287. 10.31788/RJC.2022.1516660 110 Gadag S Narayan R Nayak Y : Bioanalytical RP-HPLC method validation for resveratrol and its application to pharmacokinetic and drug distribution studies. J. Appl. Pharm. Sci. 2022;12 (2 ):158–164. 10.7324/JAPS.2021.120216 111 Patil PH Desai M Rao RR : Assessment of pH-shift drug interactions of palbociclib by in vitro micro-dissolution in bio relevant media: An analytical QbD-driven RP-HPLC method optimization. J. Appl. Pharm. Sci. 2022;12 (5 ):78–87. 10.7324/JAPS.2022.120505 112 Goudar N Tejas B Sathyanarayana MB : QUANTITATIVE DETERMINATION AND VALIDATION OF ETORICOXIB AND PARACETAMOL COMBINED TABLET DOSAGE FORM BY REVERSE PHASE-HPLC. Rasayan J. Chem. 2022;15 (3 ):1702–1708. 10.31788/RJC.2022.1537027 113 Gopalan D Patil PH Jagadish PC : QbD-driven HPLC method for the quantification of rivastigmine in rat plasma and brain for pharmacokinetics study. J. Appl. Pharm. Sci. 2022;12 (6 ):56–067. 10.7324/JAPS.2022.120606 114 Peraman R Chiranjeevi P Reddy YP : Beta-Alanine and Tris-(hydroxyl methyl) Aminomethane as Peak Modifiers in the Development of RP-HPLC Methods Using Aceclofenac and Haloperidol Hydrochloride as Exemplar Drugs. J. Chromatogr. Sci. 2021;59 (10 ):899–908. 10.1093/chromsci/bmab010 33618356 115 Arumugam K Chamallamudi MR Gilibili RR : Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS. Biomed. Chromatogr. 2011;25 (3 ):353–361. 10.1002/bmc.1455 20540167 116 Jitta SR Salwa KL Gangurde PK : Development and Validation of High-Performance Liquid Chromatography Method for the Quantification of Remdesivir in Intravenous Dosage Form. Assay Drug Dev. Technol. 2021;19 (8 ):475–483. 10.1089/adt.2021.074 34665025 117 Kumar G Mullick P Nandakumar K : Box–Behnken Design-Based Development and Validation of a Reverse-Phase HPLC Analytical Method for the Estimation of Paclitaxel in Cationic Liposomes. Chromatographia. 2022;85 (7 ):629–642. 10.1007/s10337-022-04172-w 118 Naik S Mullick P Mutalik SP : Full Factorial Design for Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Timolol Maleate in Surfactant-Based Elastic Nano-Vesicular Systems. J. Chromatogr. Sci. 2022;60 (6 ):584–594. 10.1093/chromsci/bmab101 34435614 119 Kolate NS Mishra H Kini SG : A Validated RP-HPLC Method for Quantification of Steviol Glycoside: Rebaudioside A in Extracts of Stevia Rebaudiana Leaf. Chromatographia. 2021;84 (1 ):21–26. 10.1007/s10337-020-03980-2 120 Sravani AB Mathew EM Ghate V : A Sensitive Spectrofluorimetric Method for Curcumin Analysis. J. Fluoresc. 2022;32 (4 ):1517–1527. 10.1007/s10895-022-02947-w 35526207 121 Navya Sree KS Girish Pai K Verma R : Validation of HPLC method for quantitative determination of gefitinib in polymeric nanoformulation. Pharm. Chem. J. 2017;51 (2 ):159–163. 10.1007/s11094-017-1575-6 122 Rathod RU Navyasree KS Bhat K : Quantification of Sofosbuvir in Human Plasma: RP-HPLC Method Development and Validation. Pharm. Chem. J. 2018;52 (7 ):663–673. 10.1007/s11094-018-1878-2 123 Phani Sekhar Reddy G Navyasree KS Jagadish PC : Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations. Pharm. Chem. J. 2018;52 (7 ):674–679. 10.1007/s11094-018-1879-1 124 Sushmitha GS Pai G Krishna M : Development of multiple time point stability indicating assay method and validation of nabumetone by RP-HPLC. Res J Pharm Technol. 2018;11 (11 ):4813–4820. 10.5958/0974-360X.2018.00875.2 125 Avadhani KS Amirthalingam M Reddy MS : Development and validation of RP-HPLC method for estimation of epigallocatechin -3-gallate (EGCG) in lipid based nanoformulations. Res J Pharm Technol. 2016;9 (6 ):725–730. 10.5958/0974-360X.2016.00138.4 126 Wang S Liu C Chen Y : Aggregation of Hydroxypropyl Methylcellulose Acetate Succinate under Its Dissolving pH and the Impact on Drug Supersaturation. Mol. Pharm. 2018;15 (10 ):4643–4653. 10.1021/acs.molpharmaceut.8b00633 30130968 127 Wang M Jiang J Cai Y : In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. Biomed. Chromatogr. 2018;32 (12 ):e4364. 10.1002/bmc.4364 30119143 128 Verweij-van Wissen CPWGM Burger DM Verweij PE : Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012;887-888 :79–84. 10.1016/j.jchromb.2012.01.015 22336695 129 Xiao Y Xu YK Pattengale P : A Rapid High-Performance LC-MS/MS Method for Therapeutic Drug Monitoring of Voriconazole, Posaconazole, Fluconazole, and Itraconazole in Human Serum. J. Appl. Lab. Med. 2017;1 (6 ):626–636. 10.1373/jalm.2016.022756 33379821 130 Yang M Dong Z Zhang Y : Preparation and evaluation of posaconazole-loaded enteric microparticles in rats. Drug Dev. Ind. Pharm. 2017;43 (4 ):618–627. 10.1080/03639045.2016.1275667 28005452 131 Yang Y Zhu X Zhang F : Stability-indicating HPLC method development and structural elucidation of novel degradation products in posaconazole injection by LC-TOF/MS, LC-MS/MS and NMR. J. Pharm. Biomed. Anal. 2016;125 :165–177. 10.1016/j.jpba.2016.03.034 27023129 132 Yoon SJ Lee K Oh J : Experience with therapeutic drug monitoring of three antifungal agents using an LC-MS/MS method in routine clinical practice. Clin. Biochem. 2019;70 :14–17. 10.1016/j.clinbiochem.2019.06.003 31175859 133 Zhang M Moore GA Barclay ML : A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. Antimicrob. Agents Chemother. 2013;57 (1 ):484–489. 10.1128/AAC.00768-12 23147736 134 Zhong W Yang X Tong W : Structural characterization of a novel degradant of the antifungal agent posaconazole. J. Pharm. Biomed. Anal. 2012;66 :40–49. 10.1016/j.jpba.2012.02.023 22464557